Encompass Health Research and Development Expenses 2010-2024 | EHC

Encompass Health annual/quarterly research and development expenses history and growth rate from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
  • Encompass Health research and development expenses for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Encompass Health research and development expenses for the twelve months ending September 30, 2024 were $0M, a NAN% increase year-over-year.
  • Encompass Health annual research and development expenses for 2023 were $0B, a NAN% decline from 2022.
  • Encompass Health annual research and development expenses for 2022 were $0B, a NAN% decline from 2021.
  • Encompass Health annual research and development expenses for 2021 were $0B, a NAN% decline from 2020.
Encompass Health Annual Research and Development Expenses
(Millions of US $)
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Encompass Health Quarterly Research and Development Expenses
(Millions of US $)
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $9.629B $4.801B
Encompass Health Corporation is a provider of integrated healthcare services. It offers both facility-based and home-based patient care through its network of inpatient rehabilitation hospitals, home health agencies and hospice agencies. The company delivers high-quality, cost-effective, integrated care in the healthcare space. It provides a continuum of facility-based and home-based post-acute services for its patients and their families, which will gain more prevalence as coordinated care and integrated delivery payment models, such as accountable care organizations and bundled payment arrangements. The company operates through two segments: Inpatient Rehabilitation as well as Home Health and Hospice business.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.703B 0.00
Quest Diagnostics (DGX) United States $17.349B 17.58
DaVita (DVA) United States $14.249B 18.43
Chemed (CHE) United States $8.394B 25.80
Elanco Animal Health (ELAN) United States $6.076B 14.46
Option Care Health (OPCH) United States $5.267B 24.96
RadNet (RDNT) United States $4.972B 110.11
LifeStance Health (LFST) United States $3.092B 0.00
Amedisys (AMED) United States $3.023B 21.51
Addus HomeCare (ADUS) United States $2.290B 26.87
Astrana Health (ASTH) United States $2.076B 28.39
U.S Physical Therapy (USPH) United States $1.337B 35.14
Pennant (PNTG) United States $0.945B 38.21
Aveanna Healthcare Holdings (AVAH) United States $0.945B 0.00
Atai Life Sciences (ATAI) Germany $0.252B 0.00
Bioqual (BIOQ) United States $0.055B 0.00
Daxor (DXR) United States $0.038B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
IMAC Holdings (BACK) United States $0.002B 0.00
Psychemedics (PMD) United States $0.000B 0.00